Share Name Share Symbol Market Type Share ISIN Share Description
Constellation Healthcare Technologies LSE:CHT London Ordinary Share USU210051004 CMN SHS USD0.0001 (DI/REG S)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 202.00p 197.00p 207.00p 202.00p 202.00p 202.00p 11,669 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 52.1 7.7 7.5 22.5 184.54

Constellation Healthcare (CHT) Latest News

More Constellation Healthcare News
Constellation Healthcare Takeover Rumours

Constellation Healthcare (CHT) Share Charts

1 Year Constellation Healthcare Chart

1 Year Constellation Healthcare Chart

1 Month Constellation Healthcare Chart

1 Month Constellation Healthcare Chart

Intraday Constellation Healthcare Chart

Intraday Constellation Healthcare Chart

Constellation Healthcare (CHT) Discussions and Chat

Constellation Healthcare Forums and Chat

Date Time Title Posts
17/10/201623:29Constellation Healthcare Technologies704
03/3/201021:24Company Health Group220
03/3/201008:53****** CHARTS ******10
08/10/200719:47Company Health Group - The New Name In Town.188
26/8/200612:03Company Health with Charts & News1

Add a New Thread

Constellation Healthcare (CHT) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Constellation Healthcare trades in real-time

Constellation Healthcare (CHT) Top Chat Posts

Constellation Healthcare Daily Update: Constellation Healthcare Technologies is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker CHT. The last closing price for Constellation Healthcare was 202p.
Constellation Healthcare Technologies has a 4 week average price of 186.25p and a 12 week average price of 163.97p.
The 1 year high share price is 215p while the 1 year low share price is currently 122.50p.
There are currently 91,357,782 shares in issue and the average daily traded volume is 34,363 shares. The market capitalisation of Constellation Healthcare Technologies is £184,542,719.64.
rivaldo: New highs now. Run your winners is my philosophy. CHT remains barely on a double-figure P/E for the year starting soon. If the markets fully cotton on to the recurring and long-term revenue model then there's no reason why the share price shouldn't re-rate further assuming no slip-ups, which there haven't been to date. It was undervalued before and is now simply making up for lost time.
rivaldo: Five trades above 200p ranging up to 209p reported after the market close - I suspect they're all Buys totalling 22,000 shares. With keen buying, cheap fundamentals and a scarcity of shares the share price will hopefully continue to move upwards.
melody9999: Maybe I should not share the whole article. But here is the conclusion So, having weighed up the risks, and the current valuation, I feel Constellation's shares are being too lowly rated at the current level. In fact, I believe that a target price of 250p is not unreasonable, implying a forward PE ratio of 11.5 for 2017, and an enterprise value to cash profit multiple of 5.3 times. Interestingly, a share price move above the all-time high of 190p dating back to May 2015 would be a very bullish sign, and one that is likely once investors cotton onto the value on offer. Offering 40 per cent upside to my target price, I rate Constellation's shares a strong buy on a bid-offer spread of 173p to 178p. I am only frustrated that I could not add them to my SIPP with idealing. Has anyone else had any problems dealing?
rivaldo: Agreed. This is a very good, earnings-enhancing - and large - acquisition, which will add almost $8m EBITDA at a cost of just $24m assuming the synergies come about, which they surely will given what's been achieved to date. The only quibbles are the share price used, which as bb2 says presumably relate to the date that negotiations commenced given the share price just three weeks ago, and the CEO's convertible loan at 7.5% with an undefined conversion price. The benefits of the deal in earnings enhancement terms are certainly persuasive overall. Forecasts for next year will probably increase from 18.84p EPS now I'd have thought.
loobrush: Excellent-bought in after results-looked to me way to cheap and believed that the company is one in the right place at the right time and could grow and grow in a wide open market. I also think that the profits could grow faster than turnover as they benefit from economies of scale. I often find that with some companies that issue great results that the share price hardly moves for a week or two, then starts rising. I think this is due to Funds taking time to to analyse data thoroughly before buying, which can then give rise to a significant share price increase. Time will tell.
rivaldo: Stifel are joint brokers to CHT. They last had a 271p target price, but I haven't seen anything from them since this in October last year - anyone got anything more recent from them? http :// "Broker Stifel has initiated coverage of Constellation Healthcare Technologies (LON:CHT) with a ‘buy’ rating and 271p a share price target. The stock would have to advance around 70% from today’s levels to match that valuation. Constellation describes itself as an RCM, or a revenue cycle management company. Essentially, what it does for the nearly 6,000 doctors on its books is bill and collect monies owed by government, insurers and patients. It also provides practice management and purchasing services. Obamacare (or the Affordable Care Act to give it its proper name), has created huge upheaval for physicians, complicating the rules on payment while forcing down remuneration. For the barely profitable small firms carrying out mission-critical billing operations, Obamacare adds a financially onerous level of bureaucracy that is often the final straw. For Constellation, it has whipped up the perfect storm – or at the very least a great backdrop to consolidate a highly fragmented market. Last month it made two acquisitions in a month at a total cost of US$32mln. Meanwhile in March it completed its biggest deal to date with the purchase of New York-based Physicians Practice Plus for US$20mln. Stifel’s Ken Rumph estimates that, including the contribution of the new businesses, Constellation trading on a very modest enterprise multiple of just 4.5 times and a price to earnings multiple of 10 times. “Constellation is rolling up a large, growing, sticky and fragmented market for revenue cycle (billing) management in the USA,” said Stifel analyst Rumph. "
adamb1978: Saucepan: Regarding your question: "I think I have now learned not to invest in US companies listed on AIM. What is it that does not pass muster and prevents them from listing in their home country with a much bigger investor and funding base?" Are you familiar with NYSE and Nasdaq listing rules? CHT and other companies like SOM wouldnt meet the listing requirements. Nasdaq rules are quite stringent and include things such as minimum market cap (and/or share price), 3 years of profitability etc Adam
rivaldo: Surprising given that the 15.22p EPS forecast in the thread header remains the forecast despite the fall in the pound against the dollar, which should improve the results in pure translation terms. And also given that we know that H1 trading was good from the trading statement, so next month's results should lead to a share price boost. Volumes are tiny, so I suspect it's just summer drift - any interest at ball prior to the results could lead to a good bounce back due to CHT's illiquidity, as it did recently.
rivaldo: Cheers Santangello, and welcome. Nice 25,000 share buy from yesterday just reported late. The share price should now climb steadily in the run-up to the interims in mid-September - and we may also get an acquisition or two before that if all goes well (last year there were two acquisitions in September).
dave2608: Rivaldo But they were all sells, just under £2 million's worth, which logic would tell you creates an overhang not diminishes one and the share price doesn't budge. Then about £27k's worth of buys and the share price tick upwards. Weird, I just don't get it. The only thing I can think of is that the shares are being sold by one large investor/investors to be immediately bought by another large investor. If this isn't the case, there must be some other plausible explanation. Perhaps someone can enlighten me.
Constellation Healthcare share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20161023 06:13:06